Search

Predicting regional and temporal incidence of RSV and influenza hospitalizations in a birth cohort of young Australian children

Western Australia experiences multiple climatic zones, influencing the epidemiology of respiratory viruses. We aimed to estimate the true incidence of respiratory syncytial virus and influenza hospitalizations across these different climatic regions using predictive modelling.

Clinical predictors of hypoxic pneumonia in children from the Eastern Highlands Province, Papua New Guinea: secondary analysis of two prospective observational studies

Pneumonia is the leading cause of death in young children globally and is prevalent in the Papua New Guinea highlands. We investigated clinical predictors of hypoxic pneumonia to inform local treatment guidelines in this resource-limited setting.

An infant mouse model of influenza-driven nontypeable Haemophilus influenzae colonization and acute otitis media suitable for preclinical testing of novel therapies

Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.

Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children

Invasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.

ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in children

Chris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health

Statistical considerations for the platform trial in COVID-19 vaccine priming and boosting

The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.

Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells

This study presents an optimised cultured ELISpot protocol for detecting central memory T-cell interferon gamma (IFNγ) responses against SARS-CoV-2 peptides following an initial priming with either peptides, or whole spike protein. 

Clinical trial to examine whether “mixing” COVID-19 vaccine boosters is more effective

Top infectious disease experts in Australia will lead a clinical trial to determine whether combining different Covid-19 vaccines in the nation’s booster immunisation will increase effectiveness.

Jennifer Kent

Clinical Research Manager

The Kids researchers help quantify global impact of life-saving vaccines

Researchers at The Kids Research Institute Australia have helped map the global impact of life saving vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation (EPI).